N-[2-[(2-hydroxy-3-naphthalen-1-yloxypropyl)amino]ethyl]-4-(methanesulfonamido)benzamide | 129872-39-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: N-[2-[(2-hydroxy-3-naphthalen-1-yloxypropyl)amino]ethyl]-4-(methanesulfonamido)benzamide
• CAS: 129872-39-5
• 化学式: C₂₃H₂₇N₃O₅S
• 分子量: 457.55
• InChiKey: WGTVKHAVRPKNHC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  32
• 可旋转键数：
  11
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  125
• 氢给体数：
  4
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  4-(甲基磺酰胺)苯甲酸甲酯 以 甲醇 、 水 为溶剂， 反应 23.0h， 生成 N-[2-[(2-hydroxy-3-naphthalen-1-yloxypropyl)amino]ethyl]-4-(methanesulfonamido)benzamide
  参考文献：
  名称：

  Synthesis of novel (aryloxy)propanolamines and related compounds possessing both class II and class III antiarrhythmic activity

  摘要：

  Several (aryloxy)propanolamines and related compounds (i.e. 5-13, 16-18, 20-24, 27-33, 35, 37-39, 41, and 42) were synthesized and investigated for their class III electrophysiological activity and class II (beta-blocking) effects with use of in vitro and in vivo models. Structure-activity relationships are discussed for a series of 30 compounds. A number of these compounds prolonged the action potential duration at 95% repolarization of isolated canine cardiac Purkinje fibers by 20% (C20APD95) at concentrations of less than 1.0 microM, with no significant effects on cardiac conduction. beta-Adrenergic receptor binding studies showed that some of these compounds were 2-20 times more potent for cardiac beta 1 receptors than for beta 2 receptors. In particular, compounds 32, 41, 1, and especially (S)-1 were found to be orally active class III agents in anesthetized mongrel dogs (1 or 3 mg/kg, id) and efficacious at suppressing programmed electrical stimulation induced arrhythmias in halothane-anesthetized dogs. The profile of these compounds was similar to that found for sotalol. Compound (S)-1, which was more potent than sotalol in the PES study and equieffective in the halothane/epinephrine dog model, is being investigated further as a combined class III/II antiarrhythmic agent.

  DOI：

  10.1021/jm00172a033

文献信息

• LIS, RANDALL;MORGAN, THOMAS K. (JR);MARISCA, ANTHONY J.;GOMEZ, ROBERT P.;+, J. MED. CHEM., 33,(1990) N0, C. 2883-2891
  作者：LIS, RANDALL、MORGAN, THOMAS K. (JR)、MARISCA, ANTHONY J.、GOMEZ, ROBERT P.、+

  DOI：——

  日期：——
• Synthesis of novel (aryloxy)propanolamines and related compounds possessing both class II and class III antiarrhythmic activity
  作者：Randall Lis、Thomas K. Morgan、Anthony J. Marisca、Robert P. Gomez、Joan M. Lind、David D. Davey、Gary B. Phillips、Mark E. Sullivan

  DOI：10.1021/jm00172a033

  日期：1990.10

  Several (aryloxy)propanolamines and related compounds (i.e. 5-13, 16-18, 20-24, 27-33, 35, 37-39, 41, and 42) were synthesized and investigated for their class III electrophysiological activity and class II (beta-blocking) effects with use of in vitro and in vivo models. Structure-activity relationships are discussed for a series of 30 compounds. A number of these compounds prolonged the action potential duration at 95% repolarization of isolated canine cardiac Purkinje fibers by 20% (C20APD95) at concentrations of less than 1.0 microM, with no significant effects on cardiac conduction. beta-Adrenergic receptor binding studies showed that some of these compounds were 2-20 times more potent for cardiac beta 1 receptors than for beta 2 receptors. In particular, compounds 32, 41, 1, and especially (S)-1 were found to be orally active class III agents in anesthetized mongrel dogs (1 or 3 mg/kg, id) and efficacious at suppressing programmed electrical stimulation induced arrhythmias in halothane-anesthetized dogs. The profile of these compounds was similar to that found for sotalol. Compound (S)-1, which was more potent than sotalol in the PES study and equieffective in the halothane/epinephrine dog model, is being investigated further as a combined class III/II antiarrhythmic agent.